Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Harriet M. Kluger
No relevant relationships to disclose
Margaret K. Callahan
Research Funding - Bristol-Myers Squibb
Michael Andrew Postow
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Ruth Ann Gordon
Other Remuneration - Bristol-Myers Squibb
Neil Howard Segal
No relevant relationships to disclose
Naiyer A. Rizvi
No relevant relationships to disclose
Alexander M. Lesokhin
Research Funding - Bristol-Myers Squibb
Kathleen Reed
No relevant relationships to disclose
Matthew M. Burke
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Anne Caldwell
No relevant relationships to disclose
Stephanie Anne Kronenberg
No relevant relationships to disclose
Blessing Agunwamba
No relevant relationships to disclose
William Feely
Employment or Leadership Position - Bristol-Myers Squibb
Quan Hong
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christine E. Horak
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Alan J. Korman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Mario Sznol
No relevant relationships to disclose